How many drugs treat Tinea corporis?

Drug Landscape tracks 10 marketed treatments for Tinea corporis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/tinea-corporis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tinea corporis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tinea corporis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tinea corporis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Luzu	LULICONAZOLE	Bausch Health	Azole Antifungal [EPC]		2013-01-01
Mentax	BUTENAFINE	Bayer	Benzylamine Antifungal	Cytochrome P450 2D6	1996-01-01
Naftin	NAFTIFINE	Legacy Pharma	Allylamine Antifungal	Sigma non-opioid intracellular receptor 1	1988-01-01
Exelderm	SULCONAZOLE	Journey	Azole Antifungal	Cytochrome P450 2C19	1985-01-01
Loprox	CICLOPIROX	Bausch Health	ciclopirox	Poly [ADP-ribose] polymerase 1	1982-01-01
HALOPROGIN	HALOPROGIN	Westwood Squibb	haloprogin	Adenosine receptor A3	1982-01-01
Nizoral	ketoconazole	Johnson & Johnson (Janssen)	Azole Antifungal [EPC]	Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1	1981-06-26
Lotrimin	clotrimazole	Bayer AG	Azole Antifungal [EPC]	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1975-01-01
Diprolene	BETAMETHASONE DIPROPIONATE	Merck & Co.	Corticosteroid	Glucocorticoid receptor	1975-01-01
Monistat	miconazole	Johnson & Johnson (Janssen)	Imidazole antifungal	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1974-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Tinea corporis
Bausch Health · 2 drugs in Tinea corporis
Johnson & Johnson (Janssen) · 2 drugs in Tinea corporis
Bayer AG · 1 drug in Tinea corporis
CHARTWELL RX · 1 drug in Tinea corporis
COSETTE · 1 drug in Tinea corporis
Generic (originally Merck/Upjohn) · 1 drug in Tinea corporis
JOHNSON AND JOHNSON · 1 drug in Tinea corporis
Johnson And Johnson · 1 drug in Tinea corporis
Journey · 1 drug in Tinea corporis
Legacy Pharma · 1 drug in Tinea corporis
Merck & Co. · 1 drug in Tinea corporis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tinea corporis:

Cite this brief

Drug Landscape (2026). Tinea corporis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tinea-corporis. Accessed 2026-06-10.

Tinea corporis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing